Charles River Laboratories International, Inc. (NYSE:CRL) Given Consensus Rating of “Reduce” by Analysts

Charles River Laboratories International, Inc. (NYSE:CRL) has earned an average rating of “Reduce” from the sixteen ratings firms that are presently covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a sell rating, eleven have given a hold rating and two have issued a buy rating on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $209.00.

CRL has been the topic of several research analyst reports. TD Cowen increased their target price on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research note on Monday, November 11th. CLSA cut shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price objective on the stock. in a research report on Monday, November 18th. Citigroup lowered Charles River Laboratories International from a “neutral” rating to a “sell” rating and decreased their target price for the company from $215.00 to $175.00 in a research report on Tuesday, October 1st. William Blair reiterated an “outperform” rating on shares of Charles River Laboratories International in a report on Tuesday. Finally, UBS Group restated a “neutral” rating and set a $185.00 price objective (down previously from $250.00) on shares of Charles River Laboratories International in a report on Friday.

Charles River Laboratories International Stock Performance

Shares of Charles River Laboratories International stock opened at $163.77 on Monday. The business has a 50-day moving average price of $190.64 and a two-hundred day moving average price of $198.44. Charles River Laboratories International has a 1-year low of $160.85 and a 1-year high of $275.00. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. The company has a market cap of $8.37 billion, a P/E ratio of 20.50, a PEG ratio of 6.62 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $975.99 million. During the same quarter last year, the firm posted $2.72 earnings per share. The firm’s revenue was down 1.6% on a year-over-year basis. As a group, analysts anticipate that Charles River Laboratories International will post 10.18 EPS for the current year.

Insider Transactions at Charles River Laboratories International

In other news, Director Richard F. Wallman sold 6,621 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the transaction, the director now owns 12,386 shares in the company, valued at $2,676,862.32. The trade was a 34.83 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 1.30% of the company’s stock.

Institutional Trading of Charles River Laboratories International

A number of institutional investors and hedge funds have recently modified their holdings of the business. Wellington Management Group LLP grew its stake in Charles River Laboratories International by 135,927.9% in the 3rd quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock valued at $736,819,000 after purchasing an additional 3,738,018 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in shares of Charles River Laboratories International by 40.7% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company’s stock worth $346,821,000 after buying an additional 509,163 shares during the last quarter. Marshall Wace LLP boosted its holdings in shares of Charles River Laboratories International by 24.6% in the 2nd quarter. Marshall Wace LLP now owns 825,905 shares of the medical research company’s stock worth $170,615,000 after buying an additional 163,056 shares during the last quarter. 1832 Asset Management L.P. bought a new position in Charles River Laboratories International during the second quarter valued at about $33,053,000. Finally, Earnest Partners LLC raised its position in Charles River Laboratories International by 12.4% in the second quarter. Earnest Partners LLC now owns 1,004,486 shares of the medical research company’s stock worth $207,507,000 after acquiring an additional 110,725 shares during the period. 98.91% of the stock is owned by hedge funds and other institutional investors.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).